Patent · US Active

Inhibitors of (alpha-v)(beta-6) integrin

US11040955B2 · kind B2 · utility

5Cited by

12References

59Claims

0Family size

Assignee

Morphic Therapeutic, Inc. · US

Inventors

Mark Brewer · Wallingford, GB
Matthew G. Bursavich · Tuckahoe, US
Aleksey I. Gerasyuto · Flemington, US
Kristopher N. Hahn · Medford, US
Bryce A. Harrison · Framingham, US
Kyle D. Konze · New York, US
Fu-Yang Lin · Sudbury, US
Blaise S. Lippa · Newton, US
Alexey A. Lugovskoy · Woburn, US
Bruce N. Rogers · Belmont, US
Mats A. Svensson · New York, US
Dawn M. Troast · Bedford, US

Key dates

Filing date	Feb 27, 2018
Grant date	Jun 22, 2021
Priority date	—
Expiry date	Feb 27, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.